EU Watch: Next Steps Re Controversial CMR Ban Approach, Fragrance Allergens Labeling

EU sources update Rose Sheet on contentious initiatives to cement the Commission’s pathway for banning carcinogenic, mutagenic or reprotoxic substances in cosmetics and to promote fragrance allergen awareness and risk management.

RS1807_Binoculars_286784657_1200.jpg

Cosmetics companies with EU interests could see movement by early 2019 on carcinogenic, mutagenic or reprotoxic substances and fragrance allergen labeling, according to European Commission experts.

The reps provided updates on cosmetics-relevant initiatives in a recent email exchange with Rose Sheet.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

MoCRA Implementation Delay Creates More Legal Exposure For Stakeholders – Attorney

 

The delay in implementation of MoCRA is seen by many companies as a temporary reprieve, but it does create more legal uncertainty, says attorney Marissa Alkhazov of law firm Buchalter.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By 

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

Animal Studies Would Not Provide ‘Meaningful Insights’ Into UV Filter Safety - Study

 
• By 

A new study on the safety of sunscreen filters relies on an alternative assessment methodology and concludes that six sunscreen UV filters are unlikely to be carcinogenic.

EU’s Small, Medium Beauty Industry Pushing For Clarity In Revised CPR

French SME association COSMED will push the European Commission for a “clear checklist” and criteria on how substances in the Cosmetic Products Regulation are assessed by Member States, as well as more clarity on the exemption process and timelines.

More from Policy & Regulation

Beauty Industry: Counter Impact Of State Legislation By Connecting With Lawmakers – IBA

 

Beauty stakeholders will undoubtedly feel the impact of new state laws targeting cosmetic ingredients and packaging and should therefore open lines of communication with state lawmakers.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By 

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.

House Appropriators’ $3.2Bn For FDA In FY 2026 Includes More Non-User Fee Funds Than Requested

 

A US House bill would give the FDA $33.1m more in budget authority than requested by the Trump Administration for fiscal year 2026. The measure was sent to the full House Appropriations committee on a party-line vote.